SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2015. Net product sales for HORIZANT® (gabapentin enacarbil) Extended-Release Tablets nearly doubled to $11.0 million for the third quarter of 2015 compared to $5.6 million for the same period in 2014. Total revenues for the third quarter were $11.4 million compared to $31.1 million for the same period in 2014. Revenues for the third quarter of 2014 included $25.0 million in collaboration revenue resulting from XenoPort’s license agreement with Indivior PLC.
Help employers find you! Check out all the jobs and post your resume.
